SWITCHING TO A PROTEASE INHIBITOR-CONTAINING, NUCLEOSIDE-SPARING REGIMEN

$5,120P41FY2009RRNIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Paper 38848040 Paper 37351860 Paper 36189595 Paper 35462129 Paper 33080873 Paper 32310630 Paper 30983160 Paper 29988108 Paper 29482941 Paper 28982667 Paper 28945201 Paper 28734653 Paper 28604759 Paper 27992627 Paper 27806377 Paper 27780864 Paper 27288245 Paper 27251275 Paper 27129247 Paper 26948580 Paper 26740256 Paper 26712324 Paper 26416797 Paper 26124280 Paper 26096197 Paper 25861985 Paper 25824627 Paper 25805727 Paper 25763882 Paper 25668184 Paper 25642331 Paper 25584182 Paper 25565205 Paper 25409104 Paper 25392748 Paper 25340392 Paper 25225968 Paper 25004092 Paper 24936242 Paper 24919816 Paper 24891156 Paper 24878055 Paper 24760011 Paper 24740997 Paper 24740208 Paper 24657858 Paper 24648512 Paper 24619546 Paper 24598261 Paper 24517508 Paper 24506215 Paper 24499393 Paper 24482376 Paper 24445997 Paper 24357059 Paper 24356886 Paper 24353177 Paper 24334183 Paper 24328079 Paper 24291257 Paper 24288334 Paper 24283977 Paper 24254900 Paper 24203065 Paper 24183983 Paper 24171105 Paper 24104966 Paper 24080090 Paper 24077174 Paper 24058728 Paper 24056400 Paper 24054930 Paper 24023384 Paper 23995980 Paper 23980754 Paper 23979260 Paper 23891185 Paper 23874650 Paper 23852148 Paper 23836730 Paper 23787291 Paper 23784898 Paper 23761040 Paper 23750033 Paper 23714261 Paper 23700471 Paper 23661677 Paper 23610059 Paper 23590631 Paper 23574474 Paper 23545571 Paper 23538604 Paper 23535107 Paper 23522115 Paper 23518336 Paper 23493357 Paper 23485913 Paper 23481648 Paper 23458416 Paper 23411472

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. BACKGROUND: Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication. METHODS: We evaluated the effects of nucleoside-sparing and PI-sparing regimens on fat distribution, bone mineral density, and metabolic parameters in 62 subjects, who were not selected for lipoatrophy, with advanced HIV (nadir CD4 count <or=200 cells/mm or HIV RNA level >or=80,000 copies/mL) and an undetectable HIV viral load. Participants were randomized to switch their initial successful antiretroviral regimen to open-label lopinavir/ritonavir (LPV/r) at a dose of 533/133 mg twice a day and efavirenz (EFV) at a dose of 600 mg/d (the nucleoside-sparing arm) versus EFV and 2 nucleoside analogues (the PI-sparing arm).

View original record on NIH RePORTER →